Natera reported first quarter 2026 revenue of $696.6 million, a 38.8% increase year-over-year, and a net loss per share of ($0.60). The company processed over one million tests for the first time in a single quarter, driven by strong performance in its oncology segment, and achieved positive cash inflow.
Key Highlights
- Revenue grew 38.8% year-over-year to $696.6 million, significantly exceeding the consensus estimate of $522.5 million.
- Total tests processed increased 18.5% to approximately 1.01 million, with oncology test volume surging 54.4% to a record 258,900 tests.
- The company raised its full-year 2026 revenue guidance to a range of $2.74 billion to $2.82 billion, an increase of $120 million at the midpoint.
- Natera achieved a positive cash inflow of $11.8 million for the quarter, an important step towards sustained cash flow break-even.